Obesity is associated with worse quality of life in women with gynecologic malignancies: An opportunity to improve patient-centered outcomes

Cancer

Volumn 121, Issue 3, 2015, Pages 395-402

  Doll, Kemi M ^a,b   Kalinowski, Alison K ^a   Snavely, Anna C ^c   Irwin, Debra E ^b   Bensen, Jeannette T ^c   Bae Jump, Victoria L ^a,c   Kim, Kenneth H ^a,c   Van Le, Linda ^a,c   Clarke Pearson, Daniel L ^a,c   Gehrig, Paola A ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Female genital neoplasms; Obesity; Patient centered outcomes research; Preoperative period; Quality of life

Indexed keywords

ADULT; AGED; ARTICLE; BLACK PERSON; BODY MASS; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; OBESITY; OVARY CANCER; PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; UTERINE CERVIX CANCER; UTERUS CANCER; VAGINA CANCER; VULVA CANCER; WELLBEING; COMPLICATION; GENITAL NEOPLASMS, FEMALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84921514026     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29061     Document Type: Article

References (39)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-1555.
2. Beesley VL, Eakin EG, Janda M, Battistutta D. Gynecological cancer survivors' health behaviors and their associations with quality of life. Cancer Causes Control. 2008;19:775-782.
3. Arem H, Park Y, Pelser C, et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. J Natl Cancer Inst. 2013;105:342-349.
4. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut. 2013;62:933-947.
5. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627-635.
6. Schmitz KH, Neuhouser ML, Agurs-Collins T, et al. Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst. 2013;105:1344-1354.
7. Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007;25:5106-5112.
8. Fader AN, Frasure HE, Gil KM, Berger NA, von Gruenigen VE. Quality of life in endometrial cancer survivors: what does obesity have to do with it? Obstet Gynecol Int. 2011;2011:308609.
9. Oldenburg CS, Boll D, Nicolaije KA, et al. The relationship of body mass index with quality of life among endometrial cancer survivors: a study from the population-based PROFILES registry. Gynecol Oncol. 2013;129:216-221.
10. von Gruenigen VE, Huang HQ, Gil KM, et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer. 2009;115:4857-4864.
11. Gil KM, Gibbons HE, Jenison EL, Hopkins MP, von Gruenigen VE. Baseline characteristics influencing quality of life in women undergoing gynecologic oncology surgery. Health Qual Life Outcomes. 2007;5:25.
12. von Gruenigen VE, Frasure HE, Jenison EL, Hopkins MP, Gil KM. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol. 2006;103:120-126.
13. von Gruenigen VE, Gil KM, Frasure HE, Jenison EL, Hopkins MP. The impact of obesity and age on quality of life in gynecologic surgery. Am J Obstet Gynecol. 2005;193:1369-1375.
14. Elme A, Utriainen M, Kellokumpu-Lehtinen P, et al. Obesity and physical inactivity are related to impaired physical health of breast cancer survivors. Anticancer Res. 2013;33:1595-1602.
15. Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role in breast cancer rehabilitation. Cancer. 2012;118(suppl 8):2277-2287.
16. Fang P, Tan KS, Troxel AB, Rengan R, Freedman G, Lin LL. High body mass index is associated with worse quality of life in breast cancer patients receiving radiotherapy. Breast Cancer Res Treat. 2013; 141:125-133.
17. Blanchard CM, Stein K, Courneya KS. Body mass index, physical activity, and health-related quality of life in cancer survivors. Med Sci Sports Exerc. 2010;42:665-671.
18. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
19. Cella D. FACT- En (Version 4). Copyright 1987, 1997.
20. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001;19:1809-1817.
21. Janda M, Obermair A, Cella D, Crandon AJ, Trimmel M. Vulvar cancer patients' quality of life: a qualitative assessment. Int J Gynecol Cancer. 2004;14:875-881.
22. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18:873-880.
23. Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007;110:196-202.
24. Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64:507-516.
25. Smits A, Lopes A, Das N, Bekkers R, Galaal K. The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter? Gynecol Oncol. 2014;132:137-141.
26. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039-2045.
27. Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:5337-5342.
28. Fenton BW, Palmieri P, Diantonio G, Vongruenigen V. Application of Patient-Reported Outcomes Measurement Information System to chronic pelvic pain. J Minim Invasive Gynecol. 2011;18:189-193.
29. Rothrock NE, Hays RD, Spritzer K, Yount SE, Riley W, Cella D. Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient- Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol. 2010;63:1195-1204.
30. Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28:172-191.
31. Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004;101:1051-1057.
32. Senn B, Gafner D, Happ MB, et al. The unspoken disease: symptom experience in women with vulval neoplasia and surgical treatment: a qualitative study. Eur J Cancer Care (Engl). 2011;20:747-758.
33. Vandborg MP, Christensen RD, Kragstrup J, et al. Reasons for diagnostic delay in gynecological malignancies. Int J Gynecol Cancer. 2011;21:967-974.
34. von Gruenigen VE, Huang HQ, Gil KM, Frasure HE, Armstrong DK, Wenzel LB. The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol. 2012;124:379-382.
35. Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:5605-5612.
36. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D; Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:437-443.
37. Ihemelandu CU, McQuellon R, Shen P, Stewart JH, Votanopoulos K, Levine EA. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS1HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol. 2013;20:3519-3526.
38. Doll KM, Snavely AC, Kalinowski A, et al. Preoperative quality of life and surgical outcomes in gynecologic oncology patients: a new predictor of operative risk? Gynecol Oncol. 2014;133:546-551.
39. Tao W, Lagergren J. Clinical management of obese patients with cancer. Nat Rev Clin Oncol. 2013;10:519-533.